Urinary hydroxyproline in multiple myeloma: correlation with clinical stages and bone disease.

S. Bolzonella, A. Paccagnella, L. Salvagno, V. Chiarion Sileni, P. De Besi, P. Scalella, M. V. Fiorentino

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty-four-hour urinary hydroxyproline excretion (HOP) (normal values: 6-22 mg/day/m2) was measured by the Hypronosticon test in 50 untreated patients with plasma cell myeloma. At diagnosis, HOP was elevated in 36 of 50 patients (72%) with a mean value of 35.9 mg/day/m2. Extent of bone lesions and clinical stage were accurately assessed in all patients. Higher HOP values were found in patients with a higher degree of bone lesions (multiple lytic areas and/or destruction of skeletal segments). According to clinical stages, HOP was very elevated only in stage III (mean value: 43.7); in stages I and II the mean value (25.2) was just above the normal range. Our data indicate that HOP in multiple myeloma at diagnosis is closely related to the extension of skeletal lesions and that during the clinical course it may be useful in the follow-up of bone disease.

Original languageEnglish
Pages (from-to)249-253
Number of pages5
JournalTumori
Volume70
Issue number3
Publication statusPublished - Jun 30 1984

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Urinary hydroxyproline in multiple myeloma: correlation with clinical stages and bone disease.'. Together they form a unique fingerprint.

Cite this